Market closedNon-fractional

Geron/GERN

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Geron

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Ticker

GERN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Foster City, United States

Employees

141

Geron Metrics

BasicAdvanced
$2.5B
Market cap
-
P/E ratio
-$0.34
EPS
0.42
Beta
-
Dividend rate
$2.5B
0.42
3.666
3.611
4.073
4.073
-21.38%
-28.94%
-60.04%
4,695.95
7.15
7.15
-13.22
5.26%
-0.44%
15.44%
6.10%

What the Analysts think about Geron

Analyst Ratings

Majority rating from 7 analysts.
Buy

Geron Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-18,433.33% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$300K
∞%
Net income
-$55M
6.55%
Profit margin
-18,433.33%
-∞%

Geron Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.89%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.09
-$0.08
-$0.09
-$0.09
-
Expected
-$0.08
-$0.10
-$0.11
-$0.10
-$0.10
Surprise
8.00%
-18.64%
-14.29%
-7.89%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Geron stock?

Geron (GERN) has a market cap of $2.5B as of July 04, 2024.

What is the P/E ratio for Geron stock?

The price to earnings (P/E) ratio for Geron (GERN) stock is 0 as of July 04, 2024.

Does Geron stock pay dividends?

No, Geron (GERN) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Geron dividend payment date?

Geron (GERN) stock does not pay dividends to its shareholders.

What is the beta indicator for Geron?

Geron (GERN) has a beta rating of 0.42. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Geron stock

Buy or sell Geron stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing